Mays Cancer Center at UT Health San Antonio, in partnership with the American Association for Cancer Research (AACR), is hosting the 46th annual San Antonio Breast Cancer Symposium (SABCS) at the Henry B. Gonzalez Convention Center on Dec. 5-9. This scientific and education symposium, initiated and owned by Mays Cancer Center, is the world’s largest […]
Natalie Poullard, MA, MS, CGC, a certified genetic counselor at Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, provides a brief understanding of genetic testing benefits, the types of tests available and what you can expect during an appointment. Watch here
This randomized phase III trial studies how well doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients with triple-negative breast cancer. Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether doxorubicin hydrochloride and cyclophosphamide is more effective when followed by paclitaxel alone or paclitaxel and carboplatin in treating triple-negative breast cancer.
David Gius, MD, PhD, has been awarded a $1.6 million UT System Faculty STARs award to support his research on aging and breast cancer.
The Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, was the lead site for a study evaluating Phase I and Phase III clinical trials for elacestrant, a treatment for postmenopausal women and adult men with ER+/HER2- advanced or metastatic breast cancer. The U.S. Food and Drug Administration on Jan. 27 announced it approved the […]
Researchers from the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, will present results of multiple lines of study Dec. 7-10 during the 2021 San Antonio Breast Cancer Symposium.
This is an open label phase II clinical trial to determine the efficacy, toxicity, and safety of TAK-228 plus tamoxifen in patients with newly diagnosed ER-positive, HER2-negative breast cancer.
This randomized phase III trial studies docetaxel, carboplatin, trastuzumab, and pertuzumab with estrogen deprivation to see how they work compared to docetaxel, carboplatin, trastuzumab, and pertuzumab without estrogen deprivation in treating patients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive breast cancer that is operable or has spread from where it started to nearby tissue or lymph nodes (locally advanced). Drugs used in chemotherapy, such as docetaxel, carboplatin, trastuzumab, and pertuzumab, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Estrogen can cause the growth of breast cancer cells. Hormone therapy using goserelin acetate and aromatase inhibition therapy may fight breast cancer by blocking the use of estrogen by the tumor cells. Radiation therapy uses high energy x rays to kill tumor cells. Giving combination chemotherapy and radiation therapy with or without hormone therapy may be an effective treatment for hormone receptor-positive, HER2-positive, operable or locally advanced breast cancer.
Close
